Dr Lal PathLabs Limited records revenue of Rs 703 Cr with a growth of 16.6% in Q4 FY26

Dr Lal PathLabs Limited (referred to as the "Company"; NSE: LALPATHLAB, BSE: 539524), a leading diagnostic and related healthcare service provider announces their financial results for the quarter ended March 31, 2026.

Consolidated Performance Highlights: Q4 FY26

- Revenue increased by 16.6% in Q4 FY26
- EBITDA for Q4 FY26 increased by 10.5% with a margin of 26.6%
- PAT for Q4 FY26 is Rs 132 Cr. with a margin for of 18.8%
- Final Dividend of 40% i.e. Rs. 4 per share.
- Cash and Cash equivalents as on 31st March, 2026 is Rs. 1,526 Cr.

Shares of Dr. Lal Path Labs Ltd. was last trading in BSE at Rs. 1397.50 as compared to the previous close of Rs. 1412.55. The total number of shares traded during the day was 7892 in over 861 trades.

The stock hit an intraday high of Rs. 1425.20 and intraday low of 1390.00. The net turnover during the day was Rs. 11061175.00.

Source : Equity Bulls

Keywords

DrLalPathLabs INE600L01024 HealthcareServices Q4FY26 FY2026 ResultUpdate